IL164218A0 - Use of interleukin-19 to treat ovarian cancer - Google Patents
Use of interleukin-19 to treat ovarian cancerInfo
- Publication number
- IL164218A0 IL164218A0 IL16421803A IL16421803A IL164218A0 IL 164218 A0 IL164218 A0 IL 164218A0 IL 16421803 A IL16421803 A IL 16421803A IL 16421803 A IL16421803 A IL 16421803A IL 164218 A0 IL164218 A0 IL 164218A0
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- ovarian cancer
- treat ovarian
- treat
- cancer
- Prior art date
Links
- 102000001933 Interleukin-19 Human genes 0.000 title 1
- 108050009288 Interleukin-19 Proteins 0.000 title 1
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37234402P | 2002-04-11 | 2002-04-11 | |
| PCT/US2003/010926 WO2003086298A2 (en) | 2002-04-11 | 2003-04-08 | Use of interleukin-19 to treat ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL164218A0 true IL164218A0 (en) | 2005-12-18 |
Family
ID=29250841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16421803A IL164218A0 (en) | 2002-04-11 | 2003-04-08 | Use of interleukin-19 to treat ovarian cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7074575B2 (de) |
| EP (1) | EP1496933A4 (de) |
| JP (1) | JP2005529101A (de) |
| AU (1) | AU2003223529A1 (de) |
| CA (1) | CA2480213A1 (de) |
| IL (1) | IL164218A0 (de) |
| WO (1) | WO2003086298A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1492560A4 (de) * | 2002-04-10 | 2007-05-30 | Zymogenetics Inc | Verwendung von interleukin-19 zur behandlung des zervixkarzinoms |
| JP2005529101A (ja) | 2002-04-11 | 2005-09-29 | ザイモジェネティクス インコーポレイティッド | 卵巣癌を治療するためのインターロイキン−19の使用法 |
| US9601305B2 (en) * | 2013-11-11 | 2017-03-21 | Howard Hughes Medical Institute | Specimen sample holder for workpiece transport apparatus |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| CN111228467A (zh) * | 2020-03-11 | 2020-06-05 | 白晓春 | 白介素19在制备治疗中性粒细胞减少症药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US72089A (en) * | 1867-12-10 | Improved doob-spring | ||
| US5985614A (en) * | 1996-08-30 | 1999-11-16 | Human Genome Sciences, Inc. | Polynucleotides encoding interleukin-19 |
| EP2065396A1 (de) * | 1996-08-30 | 2009-06-03 | Human Genome Sciences, Inc. | Interleukin-19 |
| US20020072089A1 (en) | 1999-11-23 | 2002-06-13 | Holtzman Douglas A. | Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor |
| EP1492560A4 (de) | 2002-04-10 | 2007-05-30 | Zymogenetics Inc | Verwendung von interleukin-19 zur behandlung des zervixkarzinoms |
| JP2005529101A (ja) | 2002-04-11 | 2005-09-29 | ザイモジェネティクス インコーポレイティッド | 卵巣癌を治療するためのインターロイキン−19の使用法 |
| US20040076606A1 (en) | 2002-09-14 | 2004-04-22 | Ming-Shi Chang | Methods of modulating inflammation by administration of interleukin-19 and inhibitors of IL-19 binding |
| AU2003290528A1 (en) * | 2002-10-15 | 2004-05-04 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods and reagents for inducing immunity |
-
2003
- 2003-04-08 JP JP2003583324A patent/JP2005529101A/ja not_active Withdrawn
- 2003-04-08 US US10/408,991 patent/US7074575B2/en not_active Expired - Fee Related
- 2003-04-08 CA CA002480213A patent/CA2480213A1/en not_active Abandoned
- 2003-04-08 WO PCT/US2003/010926 patent/WO2003086298A2/en not_active Ceased
- 2003-04-08 AU AU2003223529A patent/AU2003223529A1/en not_active Abandoned
- 2003-04-08 IL IL16421803A patent/IL164218A0/xx unknown
- 2003-04-08 EP EP03719664A patent/EP1496933A4/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1496933A4 (de) | 2007-12-12 |
| JP2005529101A (ja) | 2005-09-29 |
| AU2003223529A1 (en) | 2003-10-27 |
| US20030223958A1 (en) | 2003-12-04 |
| EP1496933A2 (de) | 2005-01-19 |
| WO2003086298A3 (en) | 2004-10-28 |
| CA2480213A1 (en) | 2003-10-23 |
| US7074575B2 (en) | 2006-07-11 |
| WO2003086298A2 (en) | 2003-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003226301A8 (en) | Method of treating cancer | |
| PL375532A1 (en) | Benzimidazol-1-yl-thiophene compounds for the treatment of cancer | |
| AU2003256847A8 (en) | Method of treating cancer | |
| EP1578346A4 (de) | Raf-mek-erk-pfad-hemmer zur behandlung von krebs | |
| IL179401A0 (en) | Therapy of platinum-resistant cancer | |
| ZA200703472B (en) | Microwave treatment of minerals | |
| IL166475A0 (en) | Improved treatment of cancer with glutamine | |
| AU2003212634A8 (en) | Compounds useful in the treatment of cancer | |
| AU2003295336A1 (en) | Use of etodoclac to treat hyperplasia | |
| IL164214A0 (en) | Use of interleukin-24 to treat ovarian cancer | |
| AU2002351374A8 (en) | Antibodies to treat cancer | |
| IL165839A0 (en) | Compounds useful for the treatment of cancer compositions thereof and methods therewith | |
| AU2003302822A8 (en) | Antibodies to treat cancer | |
| AU2003222065A8 (en) | Chemiluminescent treatment of acne | |
| IL164218A0 (en) | Use of interleukin-19 to treat ovarian cancer | |
| AU2003241346A8 (en) | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer | |
| AU2003231803A8 (en) | Treatment of cancer with mefloquire | |
| GB0329416D0 (en) | Treatment of cancer | |
| IL164099A0 (en) | Use of interleukin-19 to treat cervical cancer | |
| GB0410379D0 (en) | Treatment of cancer | |
| GB0317500D0 (en) | Treatment of bph | |
| GB0223325D0 (en) | Treating cancer | |
| GB0423273D0 (en) | Treatment of cancer | |
| GB2383538B (en) | Cancer treatment | |
| GB0327667D0 (en) | Treatment of cancer |